Mioclonías por daptomicina: Descripción de un caso

Mariano José Scolari; Débora Pellegrini

doi:10.7399/fh.11799

Mioclonías por daptomicina: Descripción de un caso

Mariano José Scolari, Débora Pellegrini

Resumen

Palabras clave

daptomicina, mioclonías, reacción adversa a drogas, reporte de caso

Texto completo:

PDF (English) PDF

Referencias

Durand GA, Raoult D, Dubourg G. Antibiotic discovery: history, methods and perspectives. Int J Antimicrob Agents. 2019;53(4):371-82. DOI: 10.1016/j.ijantimicag.2018.11.010

Kanafani Z, Boucher H, Fowler V, Cabell C, Hoen B, Miró J, et al. Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin. 2010;28(8):498-503. DOI: 10.1016/j.eimc.2009.07.015

Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673‑81. DOI: 10.1086/420818

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. DOI: 10.1038/clpt.1981.154

Durante-Mangoni E, Andini R, Parrella A, Mattucci I, Cavezza G, Senese A, et al. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. Int J Antimicrob Agents. 2016;48(1):61-8. DOI: 10.1016/j.ijantimicag.2016.04.022

Seaton RA, Menichetti F, Dalekos G, Beiras-Fernández A, Nacinovich F, Pathan R, et al. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience. Adv Ther. 2015;32(12):1192-205. DOI: 10.1007/s12325-015-0267-4

Higashi Y, Nakamura S, Tsuji Y, Ogami C, Matsumoto K, Kawago K, et al. Daptomycin- induced Eosinophilic Pneumonia and a Review of the Published Literature. Intern Med. 2018;15;57(2):253-8. DOI: 10.2169/internalmedicine.9010-17

Azanza J, Quetglas E. Seguridad de daptomicina en pacientes con insuficiencia renal. Med Clin (Barc). 2010;135(Supl3):S55-9. DOI: 10.1016/S0025-7753(10)70041-5

Villaverde Piñeiro L, Rabuñal Rey R, García Sabina A, Monte Secades R, García Pais MJ. Paralysis of the external popliteal sciatic nerve associated with daptomycin administration. J Clin Pharm Ther. 2018;43(4):578-80. DOI: 10.1111/jcpt.12666

Bitar De Zayas-Enríquez A, Soper C. Daptomycin-Induced Posterior Reversible Encephalopathy Syndrome (PRES). Case Rep Neurol Med. 2019;8756932:1-4. DOI: 10.1155/2019/8756932

DOI: http://dx.doi.org/10.7399%2Ffh.11799